Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Single Dose Promising In Phase I Study

 
• By Andrew McConaghie
  
Johnson_and_Johnson
J&J is planning to include 60,000 volunteers in its Phase III trial, more than any of the other frontrunners.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D